drugset / Trial / NCT00377923

Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers

NCT00377923

Phase 1 Completed 24 enrolled IBSA Institut Biochimique SA
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a multiple dose, observer blind, randomised, parallel groups pharmacodynamic and pharmacokinetic study to assess the endometrial effects (predecidual changes) of a new aqueous progesterone formulation administered s.c. at the dose of 25 and 50 mg/day.

Timeline

Start
2005-08
Primary completion
Completion
2006-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 25 mg Subcutaneous
Subject Progesterone Other / unclassified 50 mg Subcutaneous

Indications

No indication recorded.